Stability data required by WHO-PQP Mercy Acquaye.

Slides:



Advertisements
Similar presentations
Dr. Birgit Schmauser, BfArM, Bonn
Advertisements

Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Slide 1 of 30D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Slide 1 of 16 Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community Dar Es.
2-4 ICH Quality Guidances: an overview
API Stability Lynda Paleshnuik Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
CPH training | January |1 | Stability testing of Active pharmaceutical ingredients Hua YIN.
Finished Pharmaceutical Product Specifications
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Experience of Pre-Qualification Program.
Manufacturing Process
Batch Reworking and Reprocessing
World Health Organization
Stability testing of Finished Pharmaceutical Products
API Stability Testing WHO PQ Requirements Presented by Rutendo Kuwana Accra, Ghana December 2009.
Determine impurity level in relevant batches1
Stability studies-Regulatory evaluation & most frequently observed deficiencies-FDB experience Mercy Acquaye.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Pogány - Guilin 1/36 WHO Training Workshop on Pharmaceutical Quality, G MP and Bioequivalence with a focus on artemisinines János Pogány, pharmacist,
Reference, Retention and Reserve Samples
STABILITY STUDIES GABRIEL K. KADDU
World Health Organization
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
Assessment experience
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Pharmaceutical Development with Focus on Paediatric Formulations
Dr. Pogány - Guilin 1/61 WHO Training Workshop on Pharmaceutical Quality, G MP and Bioequivalence with a focus on artemisinines János Pogány,
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Drug Stability.
Stability Q1(R2). Role Of Stability Safety and efficacy of drug product are established during development via clinical studies Quality is established.
World Health Organization
Validation of Analytical Method
FPP Stability Lynda Paleshnuik Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Accelerated Stability Testing
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
Predicting Physical Stability in Q1A(R) Chi-wan Chen, Ph.D. Office of New Drug Chemistry Center for Drug Evaluation and Research Food and Drug Administration.
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Prequalification of Medicines Program
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Stability Trials ASEAN Guidelines. The Objective of a stability study To determine the shelf life, namely the time period of storage at a specified condition.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
Pharmaceutical Quality Control & current Good Manufacturing Practice PHT 436 Lecture 8 1.
Pharmaceutical Quality Control & current Good Manufacturing Practice PHT 436 Lecture 11 1.
Dr. Pogány - Geneva 1/30 PREQUALIFICATION OF ANTIMALARIAL DRUG PRODUCTS János Pogány, pharmacist, Ph.D. Geneva, 03 May 2004
1 TG Dekker – WHO, UkraineOctober 2005 Stability Studies (emphasis on FPPs) World Health Organization Training Workshop on Pharmaceutical Quality, GMP.
Impurities in Drugs author: srikanth N
Stability Studies : Regulatory evaluation and most frequently observed Sultan Ghani.
VICH Guidelines: Stability Testing of New Veterinary Drug Substances and Medicinal Products Mai Huynh U.S. FDA Center for Veterinary Medicine Washington.
David G. Donne, Ph.D. and Thomas J. DiFeo, Ph.D.
EQUIPMENT and METHOD VALIDATION
In the name of God. Common Technical Document On Biotech.
CAPA Central Administration of Pharmaceutical Affairs EDA The Egyptian Drug Authority NODCAR National Organization for Drug Control & Research The empowered.
Stability study of DS and DP Patchara Kootiratrakarn 30 April 2016.
HOLD-TIME STUDIES.
STABILITY ?.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Physico-chemical Control of Dosage Forms
STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) & ASSIGNING RETEST PERIOD OF API’S January, 2015.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Dr. Birgit Schmauser, BfArM, Bonn
WHO Technical Report Series, No. 953, 2009
Quality by Design.
Presentation plan General objective / scope of guideline GL 5
GL3 (R) – Stability Testing of New Veterinary Drug Substances and Medicinal Products (+ Annex GL 4 - Requirements for New Dosage Forms)
Quality guidelines on impurities
GL 51 – Statistical evaluation of stability data
GL8 (R) – Stability testing for medicated premixes
Presentation transcript:

Stability data required by WHO-PQP Mercy Acquaye

Presentation Outline Requirements for APIs  Stress testing  Regulatory stability testing Requirements for FPPs  Stability –indicating quality parameters  Selection of batches  Container closure system  Testing frequency  Storage conditions  Evaluation  Extrapolation of data

Stress testing (forced degradation) Stress testing of the API can help to identify the likely degradation products, which can in turn help establish degradation pathways and intrinsic stability of the molecule and validate the stability indicating power of the analytical procedures used. The nature of the stress testing depends on the API and type of FPP involved Degradation paths are reactions of hydrolysis, oxidation, photolysis and/or acid-base chemistry

Stress conditions To force these reactions, the API or FPP is placed in solution for eg under the ff conditions Stress factorConditions heat60 o C humidity75% RH or more acid0.1N HCL base0.1N NaOH oxidative3% H 2 O 2 photolyticMetal halide, Hg, Xe lamp or UV- B/fluorescent

The purpose is to generate a small extent of degradation i.e about 10-30% loss of active by assay In the absence of any degradation after 10 days, the API is considered stable If degradation is present but not up to 10% stress factors and /or conditions should be increased Stress testing is carried out on 1 batch of the API Photostability testing should be included (ICH Q1B)

For solid-state degradation, a solid sample of the API is placed at elevated temperatures Results from stress testing are submitted to WHO and other DRAs

Regulatory stability testing Summary of stability testing program and report of 3 batches of the API is required Data for each parameter should be discussed, trends analyzed and a re-test date proposed Information on analytical procedures used and their validation should be submitted

The general requirements are Storage temp ( o C) Relative humidity (%) Minimum time period covered by data at submission (months) Accelerated 40±2 75± 56 Intermediate 30±2 65± 512 Long term 25± 2 60± 512

Post approval stability protocol and stability testing commitment when applicable A storage statement should be proposed for the labelling, based on evaluation of stability data

Stability requirements for FPPs The characteristics of the API and dosage form will determine the design of stability studies for the FPP Studies performed on each strength and container size unless bracketing or matrixing is applied

Stability- indicating quality parameters Include those susceptible to change during storage and likely to affect quality, safety and/or efficacy Analytical procedures should be validated and stability indicating

Parameters likely to be affected by storage and/or not routinely monitored during manufacturing but indicative of the stability of the FPP include the ff:  Physical characteristics e.g. organoleptic properties, in-vitro dissolution, moisture content and change of polymorphs  Efficacy of antimicrobial agents  Chemical characteristics e.g. assay of API, content of degradation products, content of preservatives, antioxidants as well as enantiomeric purity  Study of the container and closure interaction with the contents  In-use stability data for products to be diluted or reconstituted before use

Shelf life acceptance criteria should be based on stability data Repackaging of bulk finished products require studies in the bulk container and the final container closure system

Selection of batches Data on 3 primary batches, i.e at least 1 production scale and 2 pilot scale batches Composition, batch size, batch number, manufacturing data and COA at batch release should be submitted Where possible batches of FPP should be manufactured from different batches of API

Container closure system Stability testing should be conducted on the dosage form packaged in the container closure proposed for marketing as well as any secondary packaging and label

Testing frequency For accelerated, minimum of 3 points including the initial and final time points from a 6 month period For intermediate, a minimum of 4 time points including the initial and final time points from a 12 month period Reduced designs i.e matrixing or bracketing where the frequency is reduced or certain factor combinations are not tested can be used if justified

Storage conditions To test the thermal stability and sensitivity to moisture or potential for solvent loss. Storage conditions and length of studies should cover storage, shipment and subsequent use In-use stability testing should be done on 2 batches of re-constituted or diluted FPP one of which should be investigated close to the end of the shelf life.

Significant change For FPP significant change refers to any of the ff: 5% or more change in assay from its initial value Any degradation product exceeding its acceptance criterion Failure to meet acceptance criteria for appearance, physical attributes and functionality tests (colour, phase separation, hardness) Failure to meet acceptance criteria for pH or dissolution

Evaluation Results from physical, chemical, biological and microbiological tests Specific characteristics of the dosage form e.g. dissolution rate, hardness and LOD Stability data from a minimum of 3 batches is used to establish a shelf life and storage conditions for all future batches manufactured and packaged under similar conditions The degree of variability of the batches affect the confidence that subsequent batches will remain within specification throughout the proposed shelf life.

Extrapolation of data When long term data is supported by accelerated stability data, the re-test or shelf life may be extended up to not more than 12 months beyond the period covered by long term data